



## EC member

*Congress representative*



**Director of Cancer Research Laboratory  
Faculty of Medicine, University of Iceland**

### Personal details:

**Date and place of Birth:** 14th  
December, 1948

**Contact:**  
**E-mail:** helgaogm@hi.is

### Editorial Board

- National editor and reviews editor of APMIS 1986-2006.

### ACADEMIC QUALIFICATIONS

1975 – Cand. Med. et Chir. University of Iceland.  
1979 – PhD., Department of Bacteriology, University of Edinburgh Medical School.  
1982 – Associate Member of the Royal College of Pathologists.  
1982 – General medical licence in Iceland  
1982 – Specialist licence in immunology in Iceland

### PROFESSIONAL EXPERIENCE

1975 – Junior doctor: Department of Medicine, University Hospital, Reykjavík.  
1975–1979 – Postgraduate research worker and PhD student in the Immunology Laboratory, Dept. of Bacteriology, University of Edinburgh Med. School  
1979–1981 – Lecturer in microbiology / immunology at the same Department  
1981–1982 – Departments of Surgery/Oncology, University Hospital, Reykjavík  
1982–1987 – Specialist: Virus Laboratory, Department of Microbiology, University of Iceland,  
1986-2001 – Appointed docent in cell biology at the Faculty of Medicine, University of Iceland  
2001– Professor of cell biology with 50% duties as Chairman of Committee for Post-Graduate studies.  
1987– Director of Molecular and Cell Biology Research Laboratory, Icelandic Cancer Society.  
The laboratory was transferred to the Faculty of Medicine, University of Iceland in 2007 under a new name, Cancer Research Laboratory.

### DOCTORAL EDUCATION EXPERIENCE

Mentorship: MSc.: 10 (one current), Ph.D. 7 (2 current).  
1998 – Chairman of Committee for Post-Graduate studies, Faculty of Medicine

### COMMITTEES & BOARDS

1982–1986 – Secretary and later chairman of the Icelandic Society for Immunology.  
1986–1991 – Treasurer of the Icelandic Scientific Society.  
1983–1991 – Member on the Nordic Science Policy Council.  
1984–1986 – Chairman of the Education Committee of the University Hospital, Reykjavík.  
1996-2002 – Founding member and Secretary of Icelandic Society for Cancer Research.  
1998-2004 – Secretary General of EACR  
2004-2008 – member of Executive Committee.  
2004- Member of Science Committee of University of Iceland  
2006-2011 – Chair of Science Committee of University of Iceland

### ACADEMIC AWARDS & DISTINCTIONS

Grants held include grants from the Nordic Cancer Union (Cell lines carrying the *BRCA2* founder mutation), EU grants for Nordic/European collaborative projects on cancer research based on biobanks  
Several grants from RANNÍS (recently Functional and genetic basis of monoclonal gammopathies and related B cell diseases; pH and cancer)  
University of Iceland Research Fund (recently for projects on cancer cell metabolism and effects of lichen-derived compounds).  
1999 – Order of the Falcon, awarded by the President of Iceland  
2005 – The Ása Wright Award.  
2008 – Honorary Member of the European Association for Cancer Research.

## SELECTED PUBLICATIONS

- Ögmundsdóttir, H.M.** & Weir, D.M. (1980). Mechanisms of macrophage activation. *Clin. exp. Immunol.*, 40, 223-234.
- Thorlacius S, Olafsdóttir G, Tryggvadóttir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, **Ögmundsdóttir HM**, Eyfjörd JE. 1996. A single *BRCA2* mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. *Nature Genetics*, 13, 117-119.
- Ögmundsdóttir, H.M.**, Zoëga, G.M., Gissurarson, S.R. & Ingólfssdóttir, K. 1998. Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell lines and mitogen-stimulated lymphocytes. *J. Pharmacy Pharmacol.* 50, 107-115.
- Ögmundsdóttir HM**, Sveinsdóttir S, Sigfússon Á, Skaftadóttir I, Jónasson JG, Agnarsson BA. 1999. Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2. *Clin Exp Immunol*, 117, 252-260.
- Ásgeirsson KS, Jónasson JG, Tryggvadóttir L, Ólafsdóttir K, Sigurgeirsdóttir JR, Ingvarsson S, **Ögmundsdóttir HM**. 2000. Altered expression of E-cadherin in breast cancer: patterns, mechanisms and clinical significance. *Eur J Cancer*, 36, 1098-1106.
- Guðmundsdóttir I, Jónasson JG, Sigurðsson H, Ólafsdóttir K, Tryggvadóttir L, **Ögmundsdóttir HM**. 2000. Altered expression of HLA class I antigens in breast cancer: association with prognosis. *Int J Cancer (Pred Oncol)*, 89, 500-505.
- Ögmundsdóttir HM**, Haraldsdóttir V, Jóhannesson GM, Ólafsdóttir GH, Bjarnadóttir K, Sigvaldason H, Tulinius H. 2002. Monoclonal gammopathy in Iceland: A population-based registry and follow-up. *British J Haematol*, 118, 166-173.
- Ögmundsdóttir HM**, Haraldsdóttir V, Jóhannesson GM, Ólafsdóttir G, Bjarnadóttir K, Sigvaldason, Tulinius H. 2005. Familiality of benign and malignant paraproteinaemias: a population-based cancer-registry study of multiple myeloma families. *Haematologica* 90;66-71.
- Fridriksdóttir AJR, Guðjonsson Th, Halldorsson Th, Björnsson J, Steinarsdóttir M, Johannsson O Th, **Ögmundsdóttir HM**. 2005. Establishment of three human breast epithelial cell lines derived from carriers of the 999del5 *BRCA2* Icelandic founder mutation. *In Vitro Cell Dev Biol Anim.*41:337-342.
- cytogenetics of normal and malignant mammary epithelium. *Cancer Genet Cytogenet*, 165:144-150.
- Pukkala E, Andersen A, Berglund G, Gislefoss R, Gudnason V, Hallmans G, Jellum E, Jousilahti P, Knekt P, Koskela P, Kyyrönen PP, Lenner P, Luostarinen T, Löve A, **Ögmundsdóttir HM** et al. 2007. Nordic biological specimen banks as basis for studies of cancer causes and control—more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. *Acta Oncol*, 46:286-307.
- Eysteinsdóttir JH, Freysdóttir J, Skaftadóttir I, Helgason H, Haraldsson A, **Ögmundsdóttir HM**. 2009. V $\beta$  gene usage and T regulatory cells in children following partial or total thymectomy after open heart surgery in infancy. *Scand J Immunol* 69:162-168.
- Ögmundsdóttir HM**, Björnsson J, Holbrook WP. 2009. Role of TP53 in the progression of pre-malignant and malignant oral mucosal lesions: A follow-up study of 144 patients. *J Oral Pathol Med.* 38:565-71
- Ögmundsdóttir HM**, Hilmarsdóttir H, Björnsson J, Holbrook WP. 2009. Longitudinal study of TP53 mutations in eight patients with potentially malignant oral mucosal disorders. *J Oral Pathol Med* 38:716-721.
- Steinarsdóttir M, Gudmundsson IH, Jonasson JG, Olafsdóttir EJ, Eyfjörd JE, **Ögmundsdóttir HM**. Cytogenetic polyclonality of breast carcinomas: Association with clinico-pathological characteristics and outcome. *Genes Chromosomes Cancer*. 2011 Nov;50(11):930-9. doi: 10.1002/gcc.20915. Epub 2011 Aug 24.
- Dahlström AL, Andersen K, Luostarinen T, Thoresen S, **Ögmundsdóttir H** et al. Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. *Cancer Epidemiol Biomarkers Prev.* 2011; 20: 2541-2550.
- Jonsdóttir AB, Stefansson OA, Björnsson J, **Ögmundsdóttir HM**, Eyfjörd JE. Tetraploidy in *BRCA2* breast tumours. *Eur J Cancer* 2012;48(3):305-10.
- Bessadóttir M, Egilsson M, Einarsdóttir E, Magnúsdóttir IH, **Ögmundsdóttir MH**, Omarsdóttir S, **Ögmundsdóttir HM**. Proton-Shuttling lichen compound usnic acid affects mitochondrial and lysosomal function in cancer cells. *PLoS ONE* 2012; Vol. 7(2) 12: e51296
- Kuppusamy H, **Ögmundsdóttir HM**, Baigorri E et al. Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer. *PLoS ONE*. 2014. Vol. 9 (6) e100691.
- Bessadóttir M, Skúladóttir EÁ, Gowan S, Eccles S, Ómarsdóttir S, **Ögmundsdóttir HM**. Effects of anti-proliferative lichen metabolite, protolichesterinic acid, on fatty acid synthase, cell signalling and drug response in breast cancer cells. *Phytomedicine* 2014; 21:1717-1724.